Indinavir-D-6 is a deuterated form of indinavir, an antiretroviral medication primarily used in the treatment of HIV infection. As a protease inhibitor, it works by interfering with the HIV protease enzyme, which is crucial for viral replication. The deuteration in Indinavir-D-6 involves the substitution of hydrogen atoms with deuterium, a heavier isotope of hydrogen, which can enhance the stability and metabolic profile of the compound. This modification may also aid in pharmacokinetic studies and improve the understanding of drug metabolism. Indinavir itself is characterized by its ability to inhibit viral replication effectively, but it is less commonly used today due to the development of newer antiretroviral therapies with improved efficacy and safety profiles. The chemical structure of Indinavir-D-6 retains the core features of indinavir, including its aromatic rings and functional groups, while the presence of deuterium can influence its interactions within biological systems. Overall, Indinavir-D-6 serves as a valuable tool in research and development related to HIV treatment and drug metabolism studies.

Indinavir-D-6

185897-02-3: 2,3,5-Trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl-d6)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide

Applications Member of the novel hydroxyaminopentane amide class of HIV-1 protease inhibitors. Antiviral. It is a COVID19-related research product.
References Vacca, J.P., et al.: Proc. Nat. Acad. Sci. USA, 91, 4096 (1994), Dorsey, B. D., et al.: J. Med. Chem., 37, 3443 (195), Balani, S.K., et al.: Drug Metab. Dispos., 23, 266 (1995)


CAS 185897-02-3: Indinavir-D-6

Indinavir-d6

Ref: TR-I525002

Indinavir-d6

Ref: 4Z-I-442